▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1746 by analyst upside · 2026-09-27
SRRK
Scholar Rock Holding Corporation
Healthcare · Market Cap $6B · P/E 0x
ANALYST PRICE TARGET
+44.8%
implied upside to consensus target
Current Price $48.63
Consensus Target $70.44
Bull Target $84.0
Bear Target $58.0
Analysts Covering 16
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
13
Hold
1
Sell
0
52-Week Low $27.07
52-Week High $61.76
YTD Return +13.6%
FUNDAMENTALS
Market Cap $6B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-3.31
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $27.07
52-Week High $61.76
Current Price $48.63
Bear Target $58.0
Bull Target $84.0
● Now $48.63 ● Target $70.44
TRADING DATA
Avg Volume 1.5M
YTD Return +13.6%
Analyst Count 16
Consensus Buy
Upside to Target +44.8%
Last Updated 2026-09-27

ANALYST SUMMARY

Scholar Rock Holding Corporation (SRRK) is currently trading at $48.63 with a Wall Street consensus price target of $70.44, implying potential upside of 44.8% over the next 12 months. 16 analysts currently cover SRRK, with a consensus rating of Buy - 94% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $84.0, while the most cautious has a target of $58.0.

SRRK operates in the Healthcare sector with a market capitalisation of $6B. The stock is up 13.6% year-to-date and is currently trading near the upper end of its 52-week range of $27.07 – $61.76.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

GRFS +47.8%
Grifols, S.A.
$5B · P/E 9.7x · Buy
HNGE +13.1%
Hinge Health, Inc.
$8B · P/E 11.6x · Buy
INDV +36.8%
Indivior Pharmaceuticals, Inc.
$4B · P/E 12.8x · Buy
PACS +42.9%
PACS Group, Inc.
$7B · P/E 24.2x · Buy
ATR +37.4%
AptarGroup, Inc.
$8B · P/E 22.6x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for SRRK, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Truist Securities - Reiterated
Buy → Buy 2026-09-24 Building track record
JP Morgan - Reiterated
Overweight → Overweight 2026-09-21 43% win rate (7 calls)
Evercore ISI Group - Reiterated
Outperform → Outperform 2026-09-15 Building track record
Piper Sandler - Reiterated
Overweight → Overweight 2026-09-15 14% win rate (7 calls)
Jefferies - Reiterated
Buy → Buy 2026-09-15 50% win rate (6 calls)
Wedbush - Reiterated
Outperform → Outperform 2026-09-15 Building track record
Barclays ↓ Downgrade
Overweight → Equal-Weight 2026-09-15 Building track record
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-09-15 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
63
out of 100
Coverage depth
22/30
Consensus clarity
19/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →